Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28785546 | 0.98 | SIGMAR1 (0.42) | EPHX1SIGMAR1EPHX2SHBGKDM4E | |
| SCHEMBL24065663 | 0.96 | SIGMAR1 (0.40) | EPHX1SIGMAR1EPHX2KDM4EMEN1 | |
| SCHEMBL11055827 | 0.94 | SIGMAR1 (0.39) | EPHX1SIGMAR1EPHX2SHBGKDM4E | |
| SCHEMBL20093646 | 0.92 | EPHX1 (0.42) | EPHX1SIGMAR1EPHX2CYP1A2MEN1 | |
| SCHEMBL11858592 | 0.91 | SIGMAR1 (0.45) | EPHX1SIGMAR1EPHX2CYP1A2KMT2A | |
| SCHEMBL24704673 | 0.91 | SIGMAR1 (0.45) | EPHX1SIGMAR1EPHX2CYP1A2KMT2A | |
| SCHEMBL18520254 | 0.91 | SIGMAR1 (0.45) | EPHX1SIGMAR1EPHX2CYP1A2KMT2A | |
| SCHEMBL24704621 | 0.91 | SIGMAR1 (0.45) | EPHX1SIGMAR1EPHX2CYP1A2KMT2A | |
| SCHEMBL19245329 | 0.91 | SIGMAR1 (0.45) | EPHX1SIGMAR1EPHX2CYP1A2KMT2A | |
| SCHEMBL27540335 | 0.89 | EPHX1 (0.40) | EPHX1SIGMAR1EPHX2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| CN-1898317-B | Composition and method for controlling crystallization rate of polyolefin-based resin, resin composition, and resin molded article | NEW JAPAN CHEM CO LTD | 2010-11-24 | — | — | CN | disclosed |
| US-4459424-A | SECONDARY AMINE, CARBON DISULFIDE, METAL CONTAINING CATALYST | AKZONA INCORPORATED (US) | 1984-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | EPHX1 1345/4885SIGMAR1 4015/4885EPHX2 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.